Search results
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
Zacks via Yahoo Finance· 2 hours agoBausch (BHC) delivered earnings and revenue surprises of -21.33% and 1.39%, respectively, for the...
FTC targets ‘junk patents’ on Ozempic, other top drugs
BioPharma Dive via Yahoo Finance· 1 day agoThe move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate”...
Generic Drug Giant Teva Hires New Legal Chief After DOJ Deal
Bloomberg Law· 2 days agoTeva Pharmaceutical Industries Ltd. has a new chief legal officer in David McAvoy, who succeeds David Stark as the top lawyer for the world’s largest generic drug manufacturer.
First-ever trial over Zantac cancer claims gets underway in Cook County
Chicago Sun-Times· 19 hours agoAn Illinois woman’s lawsuit claiming she developed colorectal cancer from taking the heartburn drug...
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
CNBC· 2 days agoThe Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents...
Can Ozempic Maker Novo Nordisk Keep Up Its Momentum? - What’s News - WSJ Podcasts
The Wall Street Journal· 5 hours agoEmily Field: This morning, Novo talked about a quadrupling of new patients starting Wegovy on a weekly basis in the United States. Luke Vargas: Plus, Exxon Mobil reaches an agreement to close ...
Is Bristol Myers Squibb Stock a Millionaire Maker?
Motley Fool via Yahoo Finance· 7 days agoRevenue fell by 3% last year to just over $45 billion, the second straight year that the top line has declined. The concern is that it could be the start...
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Motley Fool via Yahoo Finance· 5 hours agoWhile the Seagen acquisition contributed significantly to this top-line growth, Pfizer is projected to continue posting mid-single-digit...
FTC cracks down on drugmaker patents, including Novo's Ozempic; analysts weigh in By Investing.com
Investing.com· 2 days agoThe regulator argues that these...modify or remove entries from the Orange Book that it believes are...
Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts?
Investor's Business Daily· 2 days agoSales of generics-facing Alimta, a cancer drug, are also forecast to drop. Eli Lilly Stock Analysis...